Video

Dr. Chau on the Tolerability of Ramucirumab Plus Pembrolizumab in Gastric/GEJ Cancer

Author(s):

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the tolerability of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the tolerability of ramucirumab (Cyramza) plus pembrolizumab (Keytruda) in gastric or gastroesophageal (GEJ) cancer.

In a phase I study of the combination of ramucirumab plus pembrolizumab in patients with treatment-naïve gastric or GEJ adenocarcinoma, safety and anti-tumor activity were evaluated. Ramucirumab was administered at 8 mg/kg on days 1 and 8, and pembrolizumab at 200 mg on day 1 of week 3. PD-L1 status was assessed by DAKO PD-L1 22C3 IHC pharmDx assay.

Of 28 patients, 7 achieved an objective response, 6 that were positive for PD-L1 and 1 that was not. Additionally, median progression-free survival was 5.3 months (95% CI 3.2-1.1). At the time of data presentation at the 2018 Gastrointestinal Cancers Symposium, median overall survival had not been reached.

This combination is very well tolerated, says Chau, with very few grade 3/4 toxicities, with the most common grade 3 toxicity being hypertension. Compared to standard cytotoxic chemotherapy where there is a high rate of grade 3/4 side effects, this is a well-tolerated combination for the treatment of patients with gastric or GEJ cancer, Chau concludes. This trial is currently ongoing.

Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS